Mangoceuticals Inc
NASDAQ:MGRX
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
2.235
12.45
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Net Margin
Mangoceuticals Inc
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Net Margin Across Competitors
Country | US |
Market Cap | 5.1m USD |
Net Margin |
-1 053%
|
Country | ZA |
Market Cap | 98.2B Zac |
Net Margin |
6%
|
Country | ZA |
Market Cap | 31.9B Zac |
Net Margin |
3%
|
Country | BR |
Market Cap | 44.6B BRL |
Net Margin |
3%
|
Country | US |
Market Cap | 7.5B USD |
Net Margin |
-6%
|
Country | JP |
Market Cap | 845.2B JPY |
Net Margin |
5%
|
Country | SA |
Market Cap | 16.8B SAR |
Net Margin |
9%
|
Country | CN |
Market Cap | 27.3B CNY |
Net Margin |
6%
|
Country | MX |
Market Cap | 70.6B MXN |
Net Margin |
4%
|
Country | JP |
Market Cap | 547.7B JPY |
Net Margin |
3%
|
Country | NL |
Market Cap | 2.9B EUR |
Net Margin |
-1%
|
Mangoceuticals Inc
Glance View
Mangoceuticals, Inc. engages in developing, marketing, and selling men’s wellness products and services via a telemedicine platform. The company is headquartered in Dallas, Texas. The company went IPO on 2023-03-21. The firm has developed and is in the process of preparing to commercially market a brand of erectile dysfunction (ED) product under the brand name Mango. The Company’s Mango ED product includes the ingredients, such as Tadalafil (10 milligrams (mg)), Oxytocin (100 International units (IU)) and L-Arginine (50mg), and Tadalafil (20mg), Oxytocin (100IU) and L-Arginine (50mg). The firm connects consumers to licensed healthcare professionals through its Website at www.MangoRX.com for the provision of care via telehealth through its customer portal and provides access for customers to a licensed pharmacy for online fulfillment and distribution of certain medications that may be prescribed as part of telehealth consultations, including its Mango ED product.
See Also
Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.
Based on Mangoceuticals Inc's most recent financial statements, the company has Net Margin of -1 052.9%.